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ABSTRACT
Background. Albuminuria is an early manifestation of sickle
cell nephropathy. Prior small case series suggests benefit of hy-
droxyurea in reducing albuminuria, with a similar trend noted
in pediatric studies. We aimed to comprehensively evaluate
hydroxyurea use and prevalence of albuminuria in adult sickle
cell patients.
Methods. We performed a cross-sectional study of 149 adult
patients followed between 2000 and 2011 in a comprehensive
sickle cell clinic. All patients were assessed for albuminuria
either by direct measurement or by urinary chemical strip
(dipstick) testing. Urinary albumin-to-creatinine ratios
(UACRs) were available for 112 patients. Hydroxyurea ex-
posure was defined as ≥3 months of therapy before the as-
sessment of albuminuria. Albuminuria was defined as either
UACR ≥30 mg/g or ≥1+ proteinuria on two separate
dipsticks. We constructed a multivariate logistic regression
model to assess the association between hydroxyurea and
albuminuria.
Results. The prevalence of albuminuria was lower among pa-
tients on hydroxyurea (34.7 versus 55.4%; P = 0.01) as was
median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04).
In multivariate analysis, hydroxyurea was associated with a
lower likelihood of albuminuria (odds ratio 0.28, 95% CI:
0.11–0.75, P = 0.01), adjusting for age, angiotensin-convert-
ing enzyme inhibitor/angiotensin receptor blocker use, tri-
cuspid regurgitant jet velocity, hypertension and acute chest
syndrome.
Conclusions. In our population of sickle cell patients, those
using hydroxyurea were less than one-third as likely to exhibit
albuminuria. Hydroxyurea use may prevent development of
overt nephropathy or the progression of sickle cell disease ne-
phropathy to end-stage renal disease, and its use for this indi-
cation merits further investigation.
Keywords: albuminuria, chronic kidney disease, hydroxyurea,
nephropathy, sickle cell
INTRODUCTION
Sickle cell disease (SCD) nephropathy is a common complica-
tion of SCD, and is marked in part by repetitive vaso-occlusive
phenomena leading to ischemic injury to glomeruli and the
medullary vasa recta [1]. Ischemic renal damage leads to de-
creased urinary concentrating ability, renal tubular acidosis
and glomerular ischemia with secondary hyperfiltration
mediated by vasodilatory prostaglandins [2, 3]. Histologically,
SCD nephropathy is characterized by glomerular enlargement
and perihilar focal segmental glomerulosclerosis (FSGS) [4–6].
Microalbuminuria is an early detectable manifestation of
SCD nephropathy and occurs in ∼32–42% of adult SCD pa-
tients, but can vary depending on age and SCD genotype
[6, 7]. Microalbuminuria assessment is a sensitive way of de-
tecting glomerular injury caused by SCD before appearance of
a decline in glomerular filtration rate [7]. Overt proteinuria
may occur in 40% of older adults and has been associated
with progressive loss of renal function [5–7]. Approximately
4.2–11.6% of sickle cell anemia patients develop end-stage
renal disease, which predicts early mortality [4, 8, 9].
Few options are available for the treatment of SCD nephro-
pathy. Based upon short-term studies, angiotensin-converting
enzyme inhibitors (ACEi) may reduce overt proteinuria and
remain the mainstay of therapy [4, 5, 10, 11]. Hydroxyurea is
known to reduce the frequency of acute painful episodes, acute
chest syndrome and red blood cell transfusion requirement
[12]. Hydroxyurea also appears to reduce mortality of patients
with severe SCD [13–15]. Multiple small case series have sug-
gested a short-term benefit of hydroxyurea to reduce protein-
uria, and a similar trend has been noted in retrospective and
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We sought to analyze the association of hydroxyurea treat-
ment with albuminuria in a cohort of adult patients with SCD.
We hypothesized that the use of hydroxyurea is associated
with decreased frequency and severity of proteinuria after con-
trolling for other factors that affect protein excretion.
MATERIALS AND METHODS
Patient population
Patients with SCD aged 18 years or older identified between
2000 and 2011 and followed at the University of North Caro-
lina at Chapel Hill were included in this cross-sectional study.
Some patients were recruited as part of a prior study to evalu-
ate the pathophysiology of pulmonary hypertension in SCD
[20]. For inclusion in our analysis, patients had to have a
measure of albuminuria either by direct quantification or
urinary chemical strip (dipstick) testing. Patients on renal re-
placement therapy were excluded. Samples used for data analysis
were collected during routine outpatient clinic visits. Urine
albumin measurements were taken at a time when patients were
without acute illness, such as a pain crisis, infection or gross
hematuria. All other clinical and laboratory variables were ob-
tained by retrospective review of the computerized medical
records. All aspects of the study were approved by our institu-
tional review board, in agreement with the Declaration of Hel-
sinki.
Laboratory parameters
Urinary albumin and urinary creatinine as well as other la-
boratory parameters were measured in the clinical laboratories
of the University of North Carolina Hospitals. Albuminuria
was defined as at least one urinary albumin-to-creatinine ratio
(UACR) ≥30 mg/g or ≥1+ proteinuria on two dipstick mea-
surements at least 2 months apart. In our laboratory, urinary
chemical strip testing with results ≥1+ correlate with urinary
protein concentrations ≥30 mg/dL which have ∼58% sensitiv-
ity but >95% specificity for detecting UACR ≥30 mg/g [21,
22]. This level of dipstick positivity has been used in prior
studies to identify proteinuria in sickle cell subjects [23].
For those with UACR available, albuminuria was further cate-
gorized as microalbuminuria, defined as UACR ranging from
≥30 to 299 mg/g, and macroalbuminuria, defined as UACR
≥300 mg/g. The estimated glomerular filtration rate (eGFR)
was calculated using the six-variable Modification of Diet in
Renal Disease (MDRD) Study Group formula, with correction
for the body surface area and serum albumin level [24]. Hy-
droxyurea treatment was defined as ≥3 continuous months of
therapy prior to the time of albuminuria assessment. The
usual indications to start hydroxyurea were frequent pain epi-
sodes, typically more than two to three episodes requiring
medical attention per year, frequent or severe episodes of acute
chest and occasionally severe anemia related to SCD. A diag-
nosis of systemic hypertension was made if repeated arterial
blood pressure values justified use of anti-hypertensive medica-
tion. Tricuspid regurgitant jet velocity (TRV) was assessed by
transthoracic Doppler echocardiography. With the modified
Bernoulli equation, the TRV provides a calculated estimation of
the right-ventricular-to-right-atrial systolic pressure gradient
(ΔP = 4 × TRV2) [25]. Pulmonary artery systolic pressure was
estimated by adding estimated mean atrial pressure to ΔP.
While not explicitly diagnostic, an estimated TRV of
2.5 m/s typically reflects pressures found in the mild-moderate
pulmonary hypertension range [26].
Statistical analyses
Continuous variables with normal distribution were ex-
pressed as mean ± standard deviation and compared using
Student’s t-tests. Non-parametric variables were expressed as
median [inter-quartile range (IQR)] and compared with the
Mann–Whitney U test or Kruskal–Wallis test. The Chi-square
or Fisher’s exact test was used to compare all categorical vari-
ables with the presence of albuminuria, microalbuminuria and
macroalbuminuria as well as hydroxyurea use.
In univariate analyses, primary outcome variables were
defined as the presence of albuminuria, microalbuminuria or
macroalbuminuria. For multivariate analysis, we constructed a
binary logistic regression model with albuminuria as the
outcome. We chose potential covariates identified in univariate
analyses as well as those felt to be likely to influence the outcome
as determined by directed acyclic graphs [27]. We employed
backward elimination to create the most parsimonious model.
Covariates were retained in the full model if their removal pro-
duced a >10% change in the effect estimate. Notably, we chose
not to include markers of hemolysis in our initial modeling as
we felt these were at least in part causal intermediates of the po-
tential association between hydroxyurea and albuminuria. Hy-
droxyurea may reduce erythrocyte sickling and hemolysis that
may be directly responsible for renal injury. Inclusion in multi-
variate modeling of such a covariate could remove the
detectability of an association between the primary exposure
(hydroxyurea) and the outcome (albuminuria) [27]. A P-value
<0.05 was considered as statistically significant. Confidence in-
tervals included 95% of predicted values. Statistical analyses
were performed using SPSS 16.0 (IBM Corporation, USA) soft-
ware and Stata 12.1 (StataCorp LP, USA). All authors had access
to the primary data; L.-P.L. and V.K.D. analyzed the data set.
RESULTS
Patient characteristics
A total of 149 patients were identified (95 females and 54
males), with a median age of 37 years (range from 18 to 71
years) (Table 1). The majority of patients had the HbSS geno-
type (113 HbSS, 10 HbSβ0, 7 HbSβ+ and 18 HbSC). Hydro-
xyurea was used for at least 3 months (mean length of
treatment of 73 ± 53 months) in 75 patients (50.3% of the
cohort), with a mean daily dose of 1207 ± 382 mg. Patients
were started on hydroxyurea at a median age of 27 years (IQR
21–35 years). A history of acute chest syndrome was recorded
in 123 (82.6%) patients. Forty-five of 95 patients (47.4%)
tested by echocardiography had a TRV ≥2.5 m/s. Forty (26.8%)
patients carried a diagnosis of systemic hypertension, 8 (5.4%)
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receptor blocker (ARB) and 56 (37.6%) used non-steroidal anti-
inflammatory drugs at albuminuria quantification.
Albuminuria
The prevalence of albuminuria of any degree as measured
either by UACR or dipstick was 45.0% (67 of 149 patients).
The median UACR was 80.2 mg/g (IQR: 41.4–359.4 mg/g)
in the albuminuria group compared with 6.0 mg/g (IQR:
0–15.8 mg/g) among those with normal albumin excretion (P
< 0.001) (Table 2). Microalbuminuria and macroalbuminuria
assessment was performed in 112 patients with documented
UACR but not in patients with documented dipstick only.
When categorized by severity, microalbuminuria (UACR from
30 to 299 mg/g) was present in 34.8% of patients (39 of 112)
with albumin excretion quantification, whereas macroalbumi-
nuria (UACR ≥300 mg/g) was less prevalent (16.1%).
The presence of albuminuria was associated with lower
hemoglobin (88 ± 18 versus 93 ± 17 g/L; P = 0.05), greater re-
ticulocyte percentage (7.0 versus 5.5%; P = 0.009) and a trend
toward higher lactate dehydrogenase [932 U/L (IQR: 681–
1364 U/L) versus 802 U/L (IQR: 652–1104 U/L); P = 0.06] and
total bilirubin levels [38 µmol/L (IQR: 19–51 µmol/L) versus
29 µmol/L (IQR: 17–44 µmol/L); P = 0.06], likely reflecting in-
creased hemolysis. Patients with albuminuria were prescribed
an ACEi/ARB more frequently (25.4 versus 8.5%; P = 0.005),
but received hydroxyurea less frequently (38.8 versus 59.8%; P
= 0.01).
Within categories of albuminuria (microalbuminuria versus
macroalbuminuria), several variables associated with severity
of SCD were related to severity of albuminuria (Supplemen-
tary data Table S1). Markers of hemolysis, including low
hemoglobin, high percentage of reticulocytes, high lactate de-
hydrogenase and elevated total bilirubin, were all associated
with a worsening level of albuminuria in univariate analyses.
In addition, TRV ≥2.5 m/s and increased creatinine were sig-
nificant univariate correlates of elevated albuminuria. Fifteen
(38.5%) patients with microalbuminuria and six (33.3%) with
macroalbuminuria were on hydroxyurea therapy, compared
with 34 (61.8%) who demonstrated no albuminuria during the
observation period (P = 0.03).
Hydroxyurea therapy
Hydroxyurea use was associated with a lower overall preva-
lence of albuminuria (34.7 versus 55.4%; P = 0.01) and a lower
median UACR [17.9 mg/g (IQR: 6.0–53.0 mg/g) versus 40.5
mg/g (IQR: 7.0–204.9 mg/g); P = 0.04] (Table 3). Notably, pa-
tients on hydroxyurea more commonly had a history of acute
chest syndrome history (94.7 versus 70.3%; P < 0.001), but had
lower TRV by echocardiography [2.3 m/s (IQR: 2.1–2.7 m/s)
versus 2.5 m/s (IQR: 2.3–3.0 m/s); P = 0.009]. Hydroxyurea
therapy was not associated with less hemolysis, but patients
not on hydroxyurea with albuminuria had a significant in-
crease in hemolysis markers (Supplementary data Table S2).
In addition, patients on hydroxyurea demonstrated relative
glomerular hyperfiltration compared with those not on such
treatment with the mean eGFR value of 151 ± 55 versus
128 ± 58 mL/min, P = 0.02. When evaluating categories of al-
buminuria, there was a trend toward a lower prevalence of mi-
croalbuminuria and macroalbuminuria in patients on
hydroxyurea that did not reach statistical significance. In uni-
variate regression analysis, hydroxyurea therapy was associated
with a reduced likelihood of having albuminuria [odds ratio
(OR) 0.43, 95% confidence interval (CI) 0.221–0.827; P = 0.01]
(Table 4).
In our multivariate logistic regression model, the likelihood
of having albuminuria was controlled for potential contribu-
tors to albuminuria such as age, ACEi/ARB use, TRV, hyper-
tension and history of acute chest syndrome. After adjusting
for these variables, hydroxyurea therapy remained associated
with a lower risk of albuminuria (OR: 0.28, 95% CI: 0.105–0.751;
P = 0.01) (Table 5). Simplification of this model via backward
elimination and change-in-estimate testing led to removal of age
and hypertension from the model with a similar effect size (OR:
0.31, 95% CI: 0.12–0.80; P = 0.02). We also constructed a model
in which a marker of hemolysis (lactate dehydrogenase) was
included. There was a persistent trend toward a decreased risk of
albuminuria with hydroxyurea therapy that did not reach statis-
tical significance (OR: 0.42, 95% CI: 0.15–1.18; P = 0.1).
Table 1. Patient characteristics of 149 adults with sickle cell disease
n
Clinical parameters










Hydroxyurea use (%) 149 50.3
ACEi/ARB use (%) 149 16.1
NSAID use (%) 149 37.6
Hypertension (%) 149 26.8
Systolic blood pressure (mmHg) 149 122 ± 16
Diastolic blood pressure (mmHg) 149 70 ± 12
Diabetes (%) 149 5.4
TRV ≥2.5 m/s (%) 95 47.4
Acute chest syndrome (%) 149 82.6
Laboratory parameters
UACR (mg/g) 112 30.2 (6.2–81.7)
Creatinine (µmol/L) 149 62 (53–80)
eGFR by MDRD equation (mL/min) 140 140 ± 57
TRV (m/s) 95 2.5 (2.2–2.9)
Hemoglobin (g/L) 149 91 ± 18
Percentage reticulocyte (%) 147 6.3 (4.3–8.9)
Fetal hemoglobin (%) 138 5.9 (2.9–12.8)
Lactate dehydrogenase (U/L) 139 853 (668–1159)
Total bilirubin level (µmol/L) 141 32 (17–50)
Parametric continuous variables expressed as mean ± standard deviation; non-parametric
continuous variables expressed as median (inter-quartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
NSAID, non-steroidal anti-inflammatory drug; TRV, tricuspid regurgitation jet velocity;
UACR, urinary albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate;
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DISCUSSION
In this large cohort of adult sickle cell patients, we found
hydroxyurea to be associated with a significantly lower preva-
lence of albuminuria. Moreover, this association is independ-
ent from potential variables affecting proteinuria, namely age,
ACEi/ARB use, TRV, systemic hypertension or history of acute
chest syndrome. Our findings raise questions about both the
potential mechanism by which hydroxyurea may provide
renal benefit to SCD patients and about the implications for
its use specifically for this reason.
Several potential mechanisms exist by which hydroxyurea
could affect proteinuria. Indeed, hydroxyurea is known to in-
crease fetal hemoglobin, alter expression of adhesion molecules,
decrease reticulocyte and neutrophil counts and enhance local
nitric oxide generation [12, 28]. An obvious mechanism is in-
direct, by reducing the ischemic renal injury via a decline in
sickling occurrence and reduction in hemolysis. Numerous
markers of hemolysis have been reported to be associated with
increased urinary albumin excretion [29]. In our own cohort,
patients without albuminuria demonstrated a higher hemoglo-
bin level as well as a trend toward lower lactate dehydrogenase
and bilirubin levels suggesting less hemolysis in these patients.
Whether decreased hemolysis is the primary mechanism by
which hydroxyurea is affecting albuminuria remains uncer-
tain. Our study showed no evidence of a direct association
between makers of hemolysis and use of hydroxyurea. It could
be explained partially by indications of hydroxyurea therapy,
which was frequently started in the context of recurrent
painful episodes. However, there might be a potential role of
hydroxyurea on hemolysis from our data despite no clear
direct association. Indeed, patients unexposed to hydroxyurea
with albuminuria had more hemolysis compared with untreat-
ed patients without albuminuria, with a significantly higher
median reticulocyte percent, serum lactate dehydrogenase and
total bilirubin. In other words, hydroxyurea may decrease
hemolysis in patients with albuminuria, making a significant
difference between treated and untreated patients undetect-
able. Fetal hemoglobin level and albuminuria were not directly
related in our analyses, although we observed a clear increase
in fetal hemoglobin in patients on hydroxyurea therapy, re-
gardless of their albuminuria status. This certainly reflects the
expected ‘therapeutic’ effect from the drug. In our primary
multivariate model, we purposely withheld inclusion hemoly-
sis markers as they were likely causal intermediates. With
lactate dehydrogenase added to our secondary logistic regres-
sion model, we produced a partial loss of the detectable influ-
ence of hydroxyurea on albuminuria although we still noted a
trend toward a protective effect of hydroxyurea. This
Table 2. Comparison of clinical and laboratory parameters of patients with and without albuminuria
n Albuminuria n No albuminuria P-value
Clinical parameters
Age (years) 67 38 (29–48) 82 37 (25–48) 0.5
Sex (%) 67 82 0.1
Female 56.7 69.5
Male 43.3 30.5






Hydroxyurea use (%) 67 38.8 82 59.8 0.01
ACEi/ARB use (%) 67 25.4 82 8.5 0.005
NSAID use (%) 67 31.3 82 42.7 0.2
Hypertension (%) 67 31.3 82 23.2 0.3
Systolic blood pressure (mmHg) 67 122 ± 16 82 122 ± 16 1
Diastolic blood pressure (mmHg) 67 70 ± 11 82 70 ± 12 0.8
Diabetes (%) 67 3 82 7.3 0.3
TRV ≥2.5 m/s (%) 45 55.6 50 40 0.1
Acute chest syndrome (%) 67 83.6 82 81.7 0.8
Laboratory parameters
UACR (mg/g) 57 80.2 (41.4–359.4) 55 6.0 (0–15.8) <0.001
Creatinine (µmol/L) 67 62 (53–97) 82 71 (53–80) 0.8
eGFR by MDRD equation (mL/min) 64 142 ± 70 76 138 ± 44 0.7
TRV (m/s) 45 2.5 (2.2–3.0) 50 2.4 (2.1–2.8) 0.1
Hemoglobin (g/L) 67 88 ± 18 82 93 ± 17 0.05
Percentage reticulocytea (%) 65 7.0 (4.7–10.1) 82 5.5 (3.7–8.1) 0.009
Fetal hemoglobina (%) 61 5.9 (3.0–9.3) 77 6.1 (2.6–14.5) 0.6
Lactate dehydrogenase (U/L) 60 932 (681–1364) 79 802 (652–1104) 0.06
Total bilirubin level (µmol/L) 60 55 (19–51) 81 29 (17–44) 0.06
Parametric continuous variables expressed as mean ± standard deviation; non-parametric continuous variables expressed as median (inter-quartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAID, non-steroidal anti-inflammatory drug; TRV, tricuspid regurgitation jet velocity; UACR,
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persistence suggests other potentially direct renal mechanisms
by which hydroxyurea might influence albuminuria.
One alternative mechanism could be mediated directly
through the release of nitric oxide, offsetting vasoconstrictive
effects of free heme-related nitric oxide scavenging [3, 30]. The
release of nitric oxide may also abrogate endothelial dysfunc-
tion, which has been suggested to play a role in albuminuria
[20]. Another effect may be upon podocytes themselves. SCD
nephropathy has been linked to FSGS, often the perihilar
variant, found in glomerulopathies implying adaptive changes
to hyperfiltration [3, 5, 31]. Proliferative variants of FSGS, ‘col-
lapsing’ or cellular, are marked by altered expression of prolifer-
ation markers such as cyclin D1. These result in a dysregulated
podocyte phenotype characterized by dedifferentiation and pro-
liferation [32]. Hydroxyurea may destabilize cyclin D1 thus
reducing podocyte proliferation [33].
Few treatment options specifically for SCD nephropathy
are described in the literature. Only ACEi were demonstrated
to reduce proteinuria in few studies with relatively short
follow-up [4, 5, 10, 11]. Use of ACEi in SCD patients is,
however, limited by the presence of concomitant hyperkalemia
and may be associated with a further decline of renal function
in patients with an already low GFR [7]. Hydroxyurea is
generally used in severe SCD to reduce the occurrence of vaso-
occlusive crises thereby diminishing morbidity and mortality
[13]. Currently, albuminuria and overt nephropathy by them-
selves are not indications for hydroxyurea therapy in SCD. In
this cohort, patients on hydroxyurea had features of more
Table 3. Comparison of clinical and laboratory parameters of patients on and not on hydroxyurea therapy
n Hydroxyurea n No hydroxyurea P
Microalbuminuriaa (%) 55 27.3 57 42.1 0.1
Macroalbuminuriaa (%) 55 10.9 57 21.1 0.1
Presence of albuminuria (%) 75 34.7 74 55.4 0.01
Clinical parameters
Age (years) 75 36 (28–48) 74 40 (28–49) 0.6
Sex (%) 75 74 0.5
F 61.3 66.2
M 38.7 33.8






ACEi/ARB use (%) 75 14.7 74 17.6 0.6
NSAID use (%) 75 40 74 35.1 0.5
Hypertension (%) 75 22.7 74 31.1 0.2
Systolic blood pressure (mmHg) 75 122 ± 17 74 122 ± 16 0.8
Diastolic blood pressure (mmHg) 75 71 ± 12 74 70 ± 11 0.6
Diabetes (%) 75 6.7 74 4.1 0.7
TRV ≥2.5 m/s (%) 46 37 49 57.1 0.05
Acute chest syndrome (%) 75 94.7 74 70.3 <0.001
Laboratory parameters
UACR (mg/g) 55 17.9 (6.0–53.0) 57 40.5 (7.0–204.9) 0.04
Creatinine (µmol/L) 75 62 (53–80) 74 71 (53–97) 0.1
eGFR by MDRD equation (mL/min) 70 151 ± 55 70 128 ± 58 0.02
TRV (m/s) 46 2.3 (2.1–2.7) 49 2.5 (2.3–3.0) 0.009
Hemoglobin (g/L) 75 91 ± 19 74 90 ± 16 0.8
Percentage reticulocyteb (%) 74 6.0 (4.3–8.0) 73 6.6 (4.2–9.8) 0.4
Fetal hemoglobinb (%) 69 8.8 (5.2–15.6) 69 3.2 (1.4–7.1) <0.001
Lactate dehydrogenase (U/L) 71 809 (664–1119) 68 916 (671–1385) 0.1
Total bilirubin level (µmol/L) 72 31 (17–41) 69 38 (17–56) 0.1
Parametric continuous variables expressed as mean ± standard deviation; non-parametric continuous variables expressed as median (inter-quartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAID, non-steroidal anti-inflammatory drug; TRV, tricuspid regurgitation jet velocity; UACR,
urinary albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
aMicroalbuminuria and macroalbuminuria assessment was performed in 112 patients with documented urinary albumin-to-creatinine ratio but not in patients with documented dipstick
only.
bContinuous variable.




Age 1.01 (0.981–1.032) 0.6
Hydroxyurea use 0.43 (0.221–0.827) 0.01
ACEi/ARB use 3.64 (1.409–9.421) 0.008
TRV 1.69 (0.741–3.852) 0.2
Hypertension 1.51 (0.731–3.134) 0.3
History of acute chest syndrome 1.14 (0.485–2.680) 0.8
Lactate dehydrogenase 1.00 (1.000–1.002) 0.03
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
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severe SCD (such as acute chest syndrome) likely relating to an
indication for the use of this drug. While more severe SCD
would typically be associated with albuminuria [8], we noted
reduced prevalence in those receiving hydroxyurea, despite
having an otherwise more severe phenotype.
Very small case series have suggested a short-term benefi-
cial effect of hydroxyurea on proteinuria reduction, with
similar trends noted in retrospective and prospective pediatric
studies [16–19, 34–37]. Small prospective series in pediatric
populations (a total of 20 patients) have shown an improve-
ment in proteinuria after commencing hydroxyurea [16–18].
Some of these demonstrated this effect to be beyond that
achieved by an ACEi or ARB alone [16]. Our own data demon-
strate that even after adjusting for these agents, the benefit of
hydroxyurea persisted. Larger cross-sectional studies initially
designed to describe the prevalence of albuminuria have failed
to demonstrate a correlation between albuminuria and hydro-
xyurea use [35, 38]. This finding may be partially explained by
the small number of patients on hydroxyurea and because
those cohorts were composed of pediatric patients with a
lower prevalence of albuminuria as found in adults with SCD.
The Pediatric Hydroxyurea Phase III Clinical (BABY
HUG) Trial reported the influence of hydroxyurea therapy in
193 infants and evaluated several renal outcomes such as GFR,
urine osmolality and kidney size but did not observe a sub-
stantial benefit [34, 39]. In contradistinction, our study re-
vealed an association between hydroxyurea and a separate
renal outcome - urinary protein excretion. This outcome was
not evaluated in BABY HUG likely due to the low prevalence
of albuminuria and the difficulty of obtaining urine samples in
such a young population. An observable benefit of hydroxyur-
ea in our population is likely attributable to the fact that our
population was composed exclusively of older adult patients
more likely to have end-organ damage, lending toward a
higher prevalence of albuminuria. A beneficial renal effect of
hydroxyurea may also only be demonstrable in patients who
are of sufficient age to exhibit more substantial renal disease,
i.e. proteinuria or reduced eGFR. The same rationale can be
applied to a recently published study in which a trend toward
lower microalbuminuria was observed in children under
therapy with hydroxyurea [37].
Our findings must be viewed in the context of several lim-
itations, mainly related to their retrospective and cross-sec-
tional nature. Most importantly, we are unable to discern the
longitudinal effect of hydroxyurea on commonly accepted de-
finitive renal outcomes such as loss of eGFR or end-stage renal
disease. Urine dipstick testing was used to identify albumin-
uria in a subset of the population rather than direct measure-
ment of UACR. Dipstick testing may be over-sensitive in
patients with concentrated urine, but this would be less likely in
SCD patients who frequently have a concentrating defect. We
conservatively required two dipstick tests at this level to define
albuminuria and used a cut-off that correlates well with UACR
≥30 mg/g in the general population [22]. Further, prior studies
in sickle cell nephropathy have used ≥ 1+ proteinuria by dip-
stick to identify patients with nephropathy [23]. Our definition
of hydroxyurea use was defined as 3 months of use prior to al-
buminuria assessment. Prior use of hydroxyurea in some pa-
tients categorized as non-users could have longer lasting effects.
However, we would expect this to lead to a lower prevalence of
albuminuria in non-users making it less likely to observe the
protective association of the drug. Similarly, having fewer pa-
tients of the HbSC genotype, a less severe SCD, on hydroxyurea
should diminish our ability to demonstrate a benefit of hydro-
xyurea. Despite these limitations, we still detect a statistically
significant reduction in albuminuria prevalence in hydroxyurea
users. Finally, our study does not take into account any histo-
logical measures of renal disease severity specific to SCD as sug-
gested by Guasch et al. [7]. The small number of subjects with
diabetes mellitus does reduce the possible bias of a concomitant
glomerular injury that may affect the real prevalence of SCD-
related glomerulopathy.
Our results demonstrated a decreased prevalence of albu-
minuria in adult SCD patients on hydroxyurea. After control-
ling for several relevant clinical variables, the lower likelihood
of albuminuria persisted among those patients taking hydro-
xyurea. Based upon our findings and those of prior case series,
hydroxyurea may be beneficial for prevention of SCD nephro-
pathy or delay of its progression as seen with ACEi/ARB in
diabetes. This hypothesis can best be tested by a prospective
randomized controlled clinical trial in a SCD population fol-
lowed to an age in which albuminuria is of sufficient preva-
lence. Hydroxyurea is promising particularly due to its ready
availability and relatively low cost, and our results at least
provide further incentive for physicians’ prescription of hydro-
xyurea in SCD patients and for patients’ adherence when pre-
scribed these agents. While our findings suggest that
hydroxyurea may reduce the prevalence of albuminuria in
Table 5. Multivariate determinants of albuminuria






Hydroxyurea use 0.28 (0.11–0.75) 0.01 0.31 (0.12–0.80) 0.02
ACEi/ARB use 9.13 (1.33–62.83) 0.03 4.58 (0.97–21.5) 0.05
TRV 0.84 (0.27–2.57) 0.8 0.78 (0.28–2.17) 0.6
History of acute chest syndrome 2.23 (0.60–8.26) 0.2 2.28 (0.063–8.27) 0.2
Age 1.01 (0.96–1.05) 0.8 n/a
Hypertension 0.39 (0.09–1.77) 0.2 n/a
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; TRV, tricuspid regurgitation jet velocity; n/a, not applicable.
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SCD, further investigation is needed to determine whether it
may prevent overt SCD progression to end-stage renal disease
and whether SCD nephropathy alone should be an indication
for hydroxyurea use.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
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ABSTRACT
Background. Left ventricular (LV) systolic dysfunction is an
important predictor of cardiovascular death. Global longitu-
dinal strain (GLS) is a widely available echocardiographic
technique proven to be more sensitive than conventional ejec-
tion fraction (EF) in detecting subtle changes in LV function.
However, the prognostic value of GLS in patients with chronic
kidney disease (CKD) is unknown.
Methods. We studied 447 patients from a single center who
were stratified according to estimated glomerular filtration rate
(eGFR). GLS was calculated using two-dimensional speckle
tracking and EF was measured using Simpson’s biplane. Cox
proportional hazard model was used to identify independent
predictors of survival and measures of discrimination and re-
classification were used to assess the predictive value of GLS.
Multivariable regression models were used to evaluate clinical
and laboratory factors associated with GLS.
Results. The mean EF was 58 ± 11% and GLS was
−16.6 ± 4.2%. eGFR correlated negatively with GLS (r =−0.14,
P = 0.004). Factors that were independently associated with
GLS include gender, previous myocardial infarction, eGFR
and phosphate (R2 = 0.16, P < 0.001). Sixty-four patients died
in a follow-up of 5.2 ± 1.4 years. GLS remained a significant
predictor of all-cause mortality [hazard ratio (HR) 1.08, 95%
confidence interval (CI) 1.01–1.15] following adjustment for
age, diabetes mellitus, hypertension, eGFR and left ventricular
mass index (LVMI). The strength of association between
demographic data, eGFR, LVMI and mortality increased fol-
lowing addition of GLS [c-statistic 0.68 (95% CI 0.61–0.74) to
0.71 (95% CI 0.64–0.77), P = 0.04]. Addition of GLS also de-
monstrated a 21% net reclassification improvement in risk pre-
diction for all-cause mortality over clinical factors.
Conclusions. GLS is an important predictor of all-cause mor-
tality in CKD patients. Traditional and non-traditional risk
factors such as phosphate are important determinants of GLS.
Strain assessment in CKD patients may provide greater cardio-
vascular risk stratification.
Keywords: all-cause mortality, chronic kidney disease, ejec-
tion fraction, global longitudinal strain
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in
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